Synthaverse S.A. (WSE:SVE)

Market Cap	353.85M
Revenue (ttm)	71.76M
Net Income (ttm)	7.55M
Shares Out	70.77M
EPS (ttm)	n/a
PE Ratio	79.18
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,108
Average Volume	39,649
Open	5.00
Previous Close	5.00
Day's Range	4.98 - 5.06
52-Week Range	3.95 - 5.91
Beta	-0.13
RSI	55.09
Earnings Date	Sep 9, 2025

About Revance Therapeutics

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 239
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SVE

Financial Performance

In 2024, Synthaverse's revenue was 71.76 million, an increase of 22.44% compared to the previous year's 58.61 million. Earnings were 7.55 million, an increase of 58.68%.